Market Price

65.87 

-0.77 -1.2%

as of Nov 21 '18

52 Week Range:

42.68 67.28


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., Foundation Medicine, Inc., and Daiichi Sankyo Company, Limited. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 6.49
6.56
5.14
13.55
14.00
13.91
11.78
13.11
15.00
15.05
11.88
growth rate 1.1% -21.7% 163.6% 3.3% -0.6% -15.3% 11.3% 14.4% 0.3% -21.1%
Earnings BIT 2,656.91
7,734.20
12,054.64
1,300.86
5,778.97
6,890.62
4,375.62
9,347.00
8,663.00
10,071.00
8,148.00
growth rate 191.1% 55.9% -89.2% 344.2% 19.2% -36.5% 113.6% -7.3% 16.3% -19.1%
Avg.PE 39.53
8.15
5.41
133.33
18.87
20.53
33.67
12.95
30.24
30.83
47.90
growth rate -79.4% -33.6% 2,364.5% -85.9% 8.8% 64.0% -61.5% 133.5% 2.0% 55.4%
ROA 7.05
16.34
16.20
0.79
5.93
5.84
4.16
11.69
4.44
3.98
2.61
growth rate 131.8% -0.9% -95.1% 650.6% -1.5% -28.8% 181.0% -62.0% -10.4% -34.4%
ROE 18.33
42.27
33.15
1.52
11.49
11.47
8.57
24.22
9.52
9.25
6.43
growth rate 130.6% -21.6% -95.4% 655.9% -0.2% -25.3% 182.6% -60.7% -2.8% -30.5%
ROIC 12.12
31.92
25.83
1.71
9.34
8.94
6.52
16.90
6.74
6.21
4.09
growth rate 163.4% -19.1% -93.4% 446.2% -4.3% -27.1% 159.2% -60.1% -7.9% -34.1%
Cur. Ratio 1.23
1.35
1.80
1.86
2.04
1.90
2.00
1.77
1.55
1.78
1.33
growth rate 9.8% 33.3% 3.3% 9.7% -6.9% 5.3% -11.5% -12.4% 14.8% -25.3%
Quick Ratio 0.97
0.65
1.02
1.25
1.43
1.30
1.38
1.19
1.04
1.24
0.83
growth rate -33.0% 56.9% 22.6% 14.4% -9.1% 6.2% -13.8% -12.6% 19.2% -33.1%
Leverage 2.66
2.52
1.89
1.95
1.93
2.00
2.12
2.02
2.28
2.38
2.56
growth rate -5.3% -25.0% 3.2% -1.0% 3.6% 6.0% -4.7% 12.9% 4.4% 7.6%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 2,114.77
5,205.81
5,790.01
6,512.97
6,048.60
5,663.87
6,671.00
6,518.00
7,018.00
6,873.00
growth rate 146.2% 11.2% 12.5% -7.1% -6.4% 17.8% -2.3% 7.7% -2.1%
Acct.Payable 2,625.00
2,533.00
2,807.00
3,102.00
growth rate -3.5% 10.8% 10.5%
Cur.Assets 13,900.59
22,415.79
22,914.06
26,159.90
27,481.26
28,134.05
32,605.00
29,751.00
30,614.00
24,766.00
growth rate 61.3% 2.2% 14.2% 5.1% 2.4% 15.9% -8.8% 2.9% -19.1%
Total Assets 34,325.43
88,548.36
83,397.74
82,882.92
83,674.47
83,290.52
98,167.00
101,677.00
95,377.00
87,872.00
growth rate 158.0% -5.8% -0.6% 1.0% -0.5% 17.9% 3.6% -6.2% -7.9%
Cash 3,177.06
7,340.79
8,593.56
10,667.84
10,604.77
12,315.60
7,441.00
8,524.00
6,515.00
6,092.00
growth rate 131.1% 17.1% 24.1% -0.6% 16.1% -39.6% 14.6% -23.6% -6.5%
Inventory 1,520.78
6,345.04
4,626.33
4,930.65
5,152.19
4,908.58
5,571.00
4,700.00
4,866.00
5,096.00
growth rate 317.2% -27.1% 6.6% 4.5% -4.7% 13.5% -15.6% 3.5% 4.7%
Cur.Liabilities 10,413.99
12,331.36
12,331.36
12,807.56
14,465.56
14,087.13
18,397.00
19,201.00
17,204.00
18,614.00
growth rate 18.4% 0.0% 3.9% 13.0% -2.6% 30.6% 4.4% -10.4% 8.2%
Liabilities 20,682.52
41,987.03
40,527.70
39,901.71
41,873.50
44,055.79
49,376.00
56,910.00
55,069.00
53,303.00
growth rate 103.0% -3.5% -1.5% 4.9% 5.2% 12.1% 15.3% -3.2% -3.2%
LT Debt 3,060.00
2,867.96
12,689.30
12,206.01
12,239.91
12,814.65
16,192.95
18,714.00
23,852.00
24,303.00
21,405.00
growth rate -6.3% 342.5% -3.8% 0.3% 4.7% 26.4% 15.6% 27.5% 1.9% -11.9%
Equity 18,184.70
13,642.91
46,561.33
42,870.04
42,981.20
41,800.97
39,234.73
48,647.00
44,676.00
40,088.00
34,336.00
growth rate -25.0% 241.3% -7.9% 0.3% -2.8% -6.1% 24.0% -8.2% -10.3% -14.4%
Common Shares 2,193.00
2,143.00
2,273.00
3,120.00
3,094.00
3,076.00
2,996.00
2,928.00
2,841.00
2,787.00
2,748.00
growth rate -2.3% 6.1% 37.3% -0.8% -0.6% -2.6% -2.3% -3.0% -1.9% -1.4%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Capital Expenditures 1,011.00
944.25
0.00
0.00
0.00
0.00
1,317.00
1,283.00
1,614.00
1,888.00
growth rate -6.6% -100.0% -2.6% 25.8% 17.0%
Cash Dividends 3,307.30
2,473.04
2,742.84
3,826.11
3,792.99
4,128.06
4,160.39
5,170.00
5,117.00
5,124.00
5,167.00
growth rate -25.2% 10.9% 39.5% -0.9% 8.8% 0.8% 24.3% -1.0% 0.1% 0.8%
Cash From OA 6,999.20
4,779.60
2,674.25
8,532.06
9,762.76
7,901.34
9,188.01
7,989.00
12,538.00
10,376.00
6,447.00
growth rate -31.7% -44.1% 219.0% 14.4% -19.1% 16.3% -13.1% 56.9% -17.2% -37.9%
FCF per Share 1.68
2.19
0.28
1.98
2.71
2.37
2.05
3.01
1.51
3.15
1.32
growth rate 30.4% -87.2% 607.1% 36.9% -12.6% -13.5% 46.8% -49.8% 108.6% -58.1%
Sale Purchase of Stock 1,560.00
485.00
939.00
-3,515.00
growth rate -68.9% 93.6% -100.0%
FCF 5,988.00
5,273.00
1,931.00
9,144.00
10,660.00
8,068.00
10,106.00
5,543.00
11,138.00
8,762.00
4,559.00
growth rate -11.9% -63.4% 373.5% 16.6% -24.3% 25.3% -45.2% 100.9% -21.3% -48.0%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 18,890.00
17,346.32
21,624.24
36,256.15
37,880.25
37,265.30
34,715.62
42,237.00
39,498.00
39,807.00
40,122.00
growth rate -8.2% 24.7% 67.7% 4.5% -1.6% -6.8% 21.7% -6.5% 0.8% 0.8%
Op.Income 3,675.05
1,881.91
1,868.51
6,047.03
7,769.68
5,014.22
9,347.00
8,663.00
10,071.00
8,148.00
growth rate -48.8% -0.7% 223.6% 28.5% -35.5% 86.4% -7.3% 16.3% -19.1%
IBT 7,223.33
12,054.64
1,303.23
5,782.13
6,889.83
4,371.68
17,283.00
5,401.00
4,659.00
6,521.00
growth rate 66.9% -89.2% 343.7% 19.2% -36.6% 295.3% -68.8% -13.7% 40.0%
Net Income 5,679.05
10,169.57
678.81
4,944.84
4,862.85
3,472.11
11,920.00
4,442.00
3,920.00
2,394.00
growth rate 79.1% -93.3% 628.5% -1.7% -28.6% 243.3% -62.7% -11.8% -38.9%
EPS -1.04
3.63
5.65
0.28
2.02
2.00
1.47
4.07
1.56
1.41
0.87
growth rate 100.0% 55.7% -95.0% 621.4% -1.0% -26.5% 176.9% -61.7% -9.6% -38.3%
Gross Profit 18,057.00
13,286.17
14,513.66
21,752.74
24,579.16
24,299.28
21,349.08
27,051.00
25,075.00
26,444.00
27,619.00
growth rate -26.4% 9.2% 49.9% 13.0% -1.1% -12.1% 26.7% -7.3% 5.5% 4.4%
R&D 3,494.89
4,608.20
8,759.91
6,675.38
6,439.65
5,915.37
6,532.00
6,613.00
6,784.00
9,687.00
growth rate 31.9% 90.1% -23.8% -3.5% -8.1% 10.4% 1.2% 2.6% 42.8%

Quarterly Statements

Item Name Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Earnings BIT 550.00
2,455.00
1,468.00
2,809.00
2,935.00
growth rate 346.4% -40.2% 91.4% 4.5%
Balance Sheet Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Acct.Receivable 7,671.00
6,873.00
7,245.00
7,287.00
7,374.00
growth rate -10.4% 5.4% 0.6% 1.2%
Acct.Payable 2,620.00
3,102.00
3,162.00
3,024.00
3,091.00
growth rate 18.4% 1.9% -4.4% 2.2%
Cur.Assets 27,919.00
24,766.00
24,085.00
24,064.00
26,836.00
growth rate -11.3% -2.8% -0.1% 11.5%
Total Assets 91,676.00
87,872.00
86,041.00
85,040.00
85,130.00
growth rate -4.2% -2.1% -1.2% 0.1%
Cash 7,901.00
6,092.00
4,483.00
5,310.00
7,826.00
growth rate -22.9% -26.4% 18.5% 47.4%
Inventory 5,263.00
5,096.00
5,382.00
5,178.00
5,416.00
growth rate -3.2% 5.6% -3.8% 4.6%
Cur.Liabilities 19,467.00
18,614.00
16,960.00
18,128.00
18,586.00
growth rate -4.4% -8.9% 6.9% 2.5%
Liabilities 53,177.00
53,303.00
52,140.00
52,274.00
52,474.00
growth rate 0.2% -2.2% 0.3% 0.4%
LT Debt 21,861.00
21,405.00
21,615.00
20,089.00
20,074.00
growth rate -2.1% 1.0% -7.1% -0.1%
Equity 38,248.00
34,336.00
33,668.00
32,529.00
32,422.00
growth rate -10.2% -2.0% -3.4% -0.3%
Common Shares 1,788.00
1,788.00
1,788.00
1,788.00
1,788.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Capital Expenditures 441.00
715.00
450.00
583.00
653.00
growth rate 62.1% -37.1% 29.6% 12.0%
Cash Dividends 1,283.00
1,283.00
1,299.00
1,311.00
1,285.00
growth rate 0.0% 1.3% 0.9% -2.0%
Cash From OA -1,171.00
4,015.00
1,155.00
3,382.00
2,793.00
growth rate 100.0% -71.2% 192.8% -17.4%
Sale Purchase of Stock 73.00
230.00
230.00
growth rate 215.1% 0.0%
FCF -1,612.00
3,300.00
705.00
2,799.00
2,140.00
growth rate 100.0% -78.6% 297.0% -23.5%
Income Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Sales 10,325.00
10,433.00
10,037.00
10,465.00
10,794.00
growth rate 1.1% -3.8% 4.3% 3.1%
Op.Income 550.00
2,455.00
1,468.00
2,809.00
2,935.00
growth rate 346.4% -40.2% 91.4% 4.5%
IBT 200.00
1,879.00
1,345.00
2,086.00
2,665.00
growth rate 839.5% -28.4% 55.1% 27.8%
Net Income -56.00
-1,046.00
736.00
1,707.00
1,950.00
growth rate 0.0% 100.0% 131.9% 14.2%
EPS
growth rate
Gross Profit 7,076.00
7,055.00
6,859.00
7,051.00
7,299.00
growth rate -0.3% -2.8% 2.8% 3.5%
R&D 4,136.00
2,024.00
3,194.00
1,927.00
2,072.00
growth rate -51.1% 57.8% -39.7% 7.5%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (0.13)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 53.53 53.34 16.31
EPS / Growth 1.24

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 1.0% 1.0%
Future PE 2.00 9.16 9.16
Future EPS 1.36 1.36 1.36
Value Price
MOS %
0.67
-99.0%
3.09
-95.3%
3.09
-95.3%
MOS Price 0.34 1.54 1.54
IRT 42.61 42.61 42.61

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.